Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02526290 · ClinicalTrials.gov registry record · NA
Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
A NA study, sponsored by Oculeve.
- Completed
- Registry status
- NA
- Development phase
- 97
- Enrollment target
NCT02526290 is a NA study that has completed, run by Oculeve. The registered enrollment target is 97 participants.
The verdict
NCT02526290, a NA study, has completed, sponsored by Oculeve.
- COMPLETED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
Study Summary
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
Interventions
- DEVICE Intranasal Lacrimal Neurostimulator (Oculeve)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2016-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02526290
The ClinicalTrials.gov registry entry for NCT02526290 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oculeve, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intranasal Lacrimal Neurostimulator (Oculeve) is the first listed.
NCT02526290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02526290 about?
NCT02526290 is a clinical study titled "Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator". In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
What is the current status of trial NCT02526290?
This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2015-08-31. Estimated completion is 2016-04-30.
What interventions are being tested in trial NCT02526290?
The interventions under investigation include: Intranasal Lacrimal Neurostimulator (Oculeve) (DEVICE).
Who is sponsoring clinical trial NCT02526290?
This trial is sponsored by Oculeve, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.